Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1102-1107. doi: 10.19723/j.issn.1671-167X.2018.06.029

• Article • Previous Articles     Next Articles

Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case report

Xiao-hui ZHANG1,Xue-rong DENG1,Fan Li2,Ying ZHU3,Zhuo-li ZHANG1,()   

  1. 1. Department of Rheumatology and Immunology
    2. Department of Neurology
    3. Department of Radiology, Peking University First Hospital, Beijing 100034, China
  • Received:2018-07-06 Online:2018-12-18 Published:2018-12-18
  • Contact: Zhuo-li ZHANG E-mail:zhuoli.zhang@126.com

RICH HTML

  

Abstract:

This case report concerns a 22-year-old woman who had been diagnosed with systemic lupus erythematosus (SLE). She had intermittent fever, butterfly erythema, photosensitivity, oral ulcers, and multiple arthralgia in the past seven years, but she did not adhere to regular treatments. The edema of the lower extremities and face aggravated in the recent two weeks, so she was admitted to our Department of Rheumatology and Clinical Immunology. Meanwhile, we found she had severe hypertension, the maximal blood pressure was 170/120 mmHg. The patient had high SLE disease activity (the disease activity index score was as high as 23) with blood involvement, acute renal insufficiency, multiple serous effusion and rash. After one week treatments of intravenous methylprednisolone 80 mg daily and other drugs, her conditions made some extent improvement. However, she suffered sudden epileptic attacks. No positive neuro-pathological signs were found, and the blood pressure was up to 190/130 mmHg before the onset of the seizures. Her cerebrospinal fluid (CSF) pressure was 330 mmH2O, the CSF protein level was normal value, and the white blood cell count was 0 cell/mm 3, with no signs of infection. Cranial MRI showed vasogenic edema at bilateral parietal, occipito-parietal regions, and centrum ovale. We prescribed drugs of decreasing intracranial pressure, intravenous drugs of decreasing blood pressure and midazolam for sedation, without corticosteroid impulse therapy. She recovered consciousness in the next day, without epilepsy recurrence. We eventually diagnosed it as posterior reversible encephalopathy syndrome (PRES), according to the history, laboratory results, imaging featuresand clinical outcome. PRES is a disorder of reversible subcortical vasogenic brain edema in patients with acute neurological symptoms (eg, seizures, encephalopathy, headache, and visual disturbances).PRES is mainly caused by blood pressure changes or endothelial injury, which lead to breakdown of the blood-brain barrier and subsequent brain edema. Most patients have a favourable prognosis.SLE complicated with PRES is not rare, especially in patients with disease activity, hypertension, lupus nephritis and/or renal insufficiency, and use of cytotoxic drugs, early recognition and appropriate treatment remain important. Brainstem involvement, intracranial hemorrhage, renal insufficiency and high disease activity of lupus are risk factors for poor prognosis.

Key words: Lupus erythematosus, Seizures, Encephalopathy, Neuropsychiatric systemic lupus erythematosus

CLC Number: 

  • R593.24 +1

Figure 1

Brain CT scans revealed low-density focus in parietal and occipital regions"

Figure 2

Cranial MRI showed the abnormal signals at bilateral parietal, occipito-parietal regions, and centrum ovale (arrows)"

Figure 3

Follw-up MRI reexamination demonstrated that previous lesions disappeared completely"

[1] Tay SH, Mak A . Diagnosing and attributing neuropsychiatric events to systemic lupus erythematosus:time to untie the Gordian knot[J]. Rheumatology (Oxford), 2017,56(Suppl1):i14-i23.
doi: 10.1093/rheumatology/kex017 pmid: 28339930
[2] Shankar J, Banfield J . Posterior reversible encephalopathy syndrome: a review[J]. Can Assoc Radiol J, 2017,68(2):147-153.
doi: 10.1016/j.carj.2016.08.005 pmid: 28131335
[3] Toledano M, Fugate JE . Posterior reversible encephalopathy in the intensive care unit[J]. Handb Clin Neurol, 2017,141:467-483.
doi: 10.1016/B978-0-444-63599-0.00026-0
[4] Fugate JE, Rabinstein AA . Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions[J]. Lancet Neurol, 2015,14(9):914-925.
doi: 10.1016/S1474-4422(15)00111-8 pmid: 26184985
[5] Datar S, Singh TD, Fugate JE , et al. Albuminocytologic dissociation in posterior reversible encephalopathy syndrome[J]. Mayo Clin Proc, 2015,90(10):1366-1371.
doi: 10.1016/j.mayocp.2015.07.018 pmid: 26349950
[6] Lee VH, Wijdicks EF, Manno EM , et al. Clinical spectrum of reversible posterior leukoencephalopathy syndrome[J]. Arch Neurol, 2008,65(2):205-210.
doi: 10.1016/S0887-8994(01)00265-X pmid: 18268188
[7] Varaprasad IR, Agrawal S, Prabu VN , et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus[J]. J Rheumatol, 2011,38(8):1607-1611.
doi: 10.1097/RHU.0b013e3182a21ffd pmid: 23965484
[8] Casey SO, Sampaio RC, Michel E , et al Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion re-covery MR imaging in the detection of cortical and subcortical lesions[J]. Am J Neuroradiol, 2000,21(7):1199-1206.
[9] Magnano MD, Bush TM, Herrera I , et al. Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2006,35(6):396-402.
doi: 10.1016/j.semarthrit.2006.01.002 pmid: 16765717
[10] Brady E, Parikh NS, Navi BB , et al. The imaging spectrum of posterior reversible encephalopathy syndrome: a pictorial review[J]. Clin Imaging, 2018,47:80-89.
doi: 10.1016/j.clinimag.2017.08.008 pmid: 28910681
[11] Bartynski WS, Boardman JF . Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome[J]. Am J Neuroradiol, 2007,28(7):1320-1327.
doi: 10.3174/ajnr.A0549
[12] McKinney AM, Short J, Truwit CL , et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings[J]. Am J Roentgenol, 2007,189(4):904-912.
doi: 10.2214/AJR.07.2024 pmid: 17885064
[13] Gao B, Lyu C, Lerner A , et al. Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years[J]. J Neurol Neurosurg Psychiatry, 2018,89(1):14-20.
doi: 10.1136/jnnp-2017-316225 pmid: 28794149
[14] Gatla N, Annapureddy N, Sequeira W , et al Posterior reversible encephalopathy syndrome in systemic lupus erythematosus[J]. J Clin Rheumatol, 2013,19(6):334-340.
doi: 10.1097/RHU.0b013e3182a21ffd pmid: 23965484
[15] Junewar V, Verma R, Sankhwar PL , et al. Neuroimaging features and predictors of outcome in eclamptic encephalopathy: a prospective observational study[J]. Am J Neuroradiol, 2014,35(9):1728-1734.
doi: 10.3174/ajnr.A3923 pmid: 24722310
[16] Karia SJ, Rykken JB , McKinney ZJ, et al. Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome[J]. Am J Neuroradiol, 2016,37(3):415-422.
doi: 10.3174/ajnr.A4563 pmid: 26564441
[17] Covarrubias DJ, Luetmer PH, Campeau NG . Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images[J]. Am J Neuroradiol, 2002,23(6):1038-1048.
doi: 10.1055/s-2002-32034 pmid: 12063238
[18] Schweitzer AD, Parikh NS, Askin G , et al. Imaging characteristics associated with clinical outcomes in posterior reversible encephalopathy syndrome[J]. Neuroradiology, 2017,59(4):379-386.
doi: 10.1007/s00234-017-1815-1 pmid: 28289809
[19] Rabinstein AA, Mandrekar J, Merrell R , et al. Blood pressure fluctuations in posterior reversible encephalopathy syndrome[J]. J Stroke Cerebrovasc Dis, 2012,21(4):254-258.
doi: 10.1016/j.jstrokecerebrovasdis.2011.03.011 pmid: 21536456
[20] van Beek AH, Claassen JA, Rikkert MG , et al. Cerebral auto-regulation: an overview of current concepts and methodology with special focus on the elderly[J]. J Cereb Blood Flow Metab, 2008,28(6):1071-1085.
doi: 10.1038/jcbfm.2008.13 pmid: 18349877
[21] Gao B, Lerner A, Law M . The Clinical outcome of posterior reversible encephalopathy syndrome[J]. Am J Neuroradiol, 2016,37(9):E55-E56.
doi: 10.3174/ajnr.A4853
[22] Sha Z, Moran BP , McKinney AMT, et al. Seizure outcomes of posterior reversible encephalopathy syndrome and correlations with electroencephalographic changes[J]. Epilepsy Behav, 2015,48:70-74.
doi: 10.1016/j.yebeh.2015.05.027 pmid: 26071927
[23] Legriel S, Schraub O, Azoulay E , et al. Determinants of recovery from severe posterior reversible encephalopathy syndrome[J]. PLoS One, 2012,7(9):e44534.
doi: 10.1371/journal.pone.0044534 pmid: 23024751
[24] Shaharir SS, Remli R, Marwan AA , et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases[J]. Lupus, 2013,22(5):492-496.
doi: 10.1177/0961203313478303 pmid: 23435619
[25] Damrongpipatkul U, Oranratanachai K, Kasitanon N , et al. Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study[J]. Clin Rheumatol, 2018,37(3):691-702.
doi: 10.1007/s10067-017-3892-2 pmid: 29103182
[26] Jung SM, Moon SJ, Kwok SK , et al. Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome[J]. Lupus, 2013,22(9):885-891.
doi: 10.1177/0961203313496341 pmid: 23846231
[27] Lai CC, Chen WS, Chang YS , et al. Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken), 2013,65(11):1766-1774.
doi: 10.1002/acr.22047 pmid: 23687067
[28] Budhoo A, Mody GM . The spectrum of posterior reversible encephalopathy in systemic lupus erythematosus[J]. Clin Rheumatol, 2015,34(12):2127-2134.
doi: 10.1007/s10067-015-3055-2 pmid: 26298534
[29] Ferreira TS, Reis F, Appenzeller S . Posterior reversible encephalopathy syndrome and association with systemic lupus erythematosus[J]. Lupus, 2016,25(12):1369-1376.
doi: 10.1177/0961203316643598 pmid: 27084028
[30] Merayo-Chalico J, Apodaca E, Barrera-Vargas A , et al. Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study[J]. J Neurol Neurosurg Psychiatry, 2016,87(3):287-294.
doi: 10.1136/jnnp-2014-310145 pmid: 25804426
[31] Ishimori ML, Pressman BD, Wallace DJ , et al. Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE[J]. Lupus, 2007,16(6):436-443.
doi: 10.1177/0961203307078682 pmid: 17664235
[32] Barber CE, Leclerc R, Gladman DD , et al. Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2011,41(3):353-363.
doi: 10.1016/j.semarthrit.2011.07.001 pmid: 21868061
[1] Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[2] Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[3] Zhi-jun LUO,Jia-jia WU,You SONG,Chun-li MEI,Rong DU. Systemic lupus erythematosus associated macrophage activation syndrome with neuropsychiatric symptoms: A report of 2 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1111-1117.
[4] Hai-hong YAO,Fan YANG,Su-mei TANG,Xia ZHANG,Jing HE,Yuan JIA. Clinical characteristics and diagnostic indicators of macrophage activation syndrome in patients with systemic lupus erythematosus and adult-onset Still's disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 966-974.
[5] Xiang-ge ZHAO,Jia-qing LIU,Hui-na HUANG,Zhi-min LU,Zi-ran BAI,Xia LI,Jing-jing QI. Interferon-α mediating the functional damage of CD56dimCD57+natural killer cells in peripheral blood of systemic lupus erythematosuss [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 975-981.
[6] Lin-qi ZHANG,Jing ZHAO,Hong-yan WANG,Zong-yi WANG,Ying-ni LI,Ji-yang TANG,Si-ying LI,Jin-feng QU,Ming-wei ZHAO. Relationship between anti-ENO1 antibody and systemic lupus erythematosus patients with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1099-1105.
[7] Min LI,Lin-qing HOU,Yue-bo JIN,Jing HE. Clinical and immunological characteristics of systemic lupus erythematosus with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1106-1111.
[8] Miao SHAO,Hui-fang GUO,Ling-yan LEI,Qing ZHAO,Yan-jie DING,Jin LIN,Rui WU,Feng YU,Yu-cui LI,Hua-li MIAO,Li-yun ZHANG,Yan DU,Rui-ying JIAO,Li-xia PANG,Li LONG,Zhan-guo LI,Ru LI. A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1112-1116.
[9] Jing LIU,Ai-dong LU,Ying-xi ZUO,Jun WU,Zhi-zhuo HUANG,Yue-ping JIA,Ming-ming DING,Le-ping ZHANG,Jiong QIN. Clinical characteristics and prognosis of seizures in 75 children with acute lymphoblastic leukemia [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 948-953.
[10] Yan-yan DU,Jian WANG,Lan HE,Li-na JI,Xi-wei XU. Kawasaki disease complicated with mild encephalitis/encephalopathy with a reversible splenial lesion: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 756-761.
[11] TIAN Jia-yi,ZHANG Xia,CHENG Gong,LIU Qing-hong,WANG Shi-yang,HE Jing. Serum interleukin-2 receptor α as a clinical biomarker in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1083-1087.
[12] Zheng-fang LI,Xue WU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Yan ZHONG,Xiao-mei CHEN,Xin-yan MENG. Clinical features of patients with Rhupus syndrome [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 933-937.
[13] Jian-mei ZOU,Li-jun WU,Cai-nan LUO,Ya-mei SHI,Xue WU. Relationship of serum 25- hydroxy vitamin D and systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 938-941.
[14] XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272.
[15] Yue HOU,Xu-tong ZHAO,Zhi-ying XIE,Yun YUAN,Zhao-xia WANG. Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes / myoclonus epilepsy with ragged-red fibers /Leigh overlap syndrome caused by mitochondrial DNA 8344A>G mutation [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 851-855.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!